Panobinostat, a pan-HDAC inhibitor, and TG101209, a JAK2 inhibitor, have been studied in targeting JAK2V617F-positive myeloproliferative neoplasms (MPNs). This evidence concerns the gene JAK2 and myeloproliferative disorder.